Eli Lilly said on May 27 the company received a subpoena from the U.S. Department of Justice related to the New Jersey plant that makes the Covid-19 treatment, bamlanivimab.
AstraZeneca’s $39 billion acquisition of Alexion is being investigated by the UK’s Competition and Markets Authority (CMA) to determine if the deal is anti-competitive.
New York Governor Andrew Cuomo acknowledged on Feb. 15 that his office should not have withheld data on Covid-19 nursing home deaths from state lawmakers, the public and press.
Pfizer Inc. received informal requests relating to operations in China from the U.S. Department of Justice and the U.S. Securities and Exchange Commission in June and August, respectively, according to a regulatory filing from the company.
Novartis AG agreed to pay more than $729 million to settle U.S. government charges that the company paid illegal kickbacks to doctors and patients to boost drug sales, the U.S. Department of Justice said.
Regeneron Pharmaceuticals said the company will vigorously defend federal charges of being involved in a kickback scheme to bolster sales of the blockbuster macular degeneration drug Eylea.
A Harvard professor arrested earlier this year for failing to disclose ties to China’s Thousand Talents Program was indicted for making false statements to federal authorities regarding that work in Wuhan, China.
Hector Armando Kellum, a former senior executive with the Novartis subsidiary Sandoz, pleaded guilty for his role in a price-fixing scheme for generic drugs developed by his company.
The Department of Justice leveled more charges against members of the U.S. science community who have alleged ties to China.
CVS Health Corp. and the drugstore chain’s Omnicare unit were sued by the U.S. government, which accused them of fraudulently billing Medicare and other programs for drugs for older and disabled people without valid prescriptions.